Saturday 17 October 2026
Export KRRO’s income statement to Excel — free account
Korro Bio, Inc.
KRRO Healthcare Biotechnology
Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024. In the quarter to June 2026, revenue fell 86.3%, EPS grew 61.0% and free cash flow grew 12.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.53
0.78
−8.38%
Follow KRRO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(63.46%) | (110.70%) | (87.78%) | (97.69%) | |
| (43.65%) | (69.03%) | (58.83%) | (62.03%) | ||
ROIC |
(922.96%) | 0.00% | (1,294.27%) | 0.00% | |
Return on Tangible Assets |
(81.88%) | (149.19%) | (100.28%) | (92.35%) | |
Average Days of Receivables |
20.62 | 55.33 | — | — | |
Free Cash Flow per Share |
(7.48) | (8.42) | (6.09) | (3.87) | |
Free Cash Flow |
(70.24) | (79.08) | (70.60) | (68.26) | |
Capital Expenditures |
(1.89) | (0.52) | (0.42) | (0.32) | |
| Other line items | |||||
Cash ROIC |
(36.68%) | (62.47%) | (30.22%) | (31.28%) | |
Accounts Receivable Turnover |
2.68 | 4.80 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
486.71% | 1,025.89% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
206.52% | 440.54% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
47.81% | 119.76% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.67 | 0.62 | 0.64 | |
Depreciation/Fixed assets |
0.16 | 0.46 | 0.42 | 0.34 | |
Capex/Depreciation |
(0.50) | (0.14) | (0.13) | (0.13) | |
Revenue per Share |
1.55 | 0.68 | 0.00 | 0.00 | |
Operating CF per Share |
(7.28) | (8.36) | (6.05) | (3.86) | |
Capex per Share |
(0.20) | (0.06) | (0.04) | (0.02) | |
Capex to Sales |
0.13 | 0.08 | 0.00 | 0.00 |
Columns are period end dates